Examples of clinical trials supplied by pharma
April 2021, Genmab
FDA approved tisotumab vedotin for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
In recurrent and metastatic cervical cancer we have less therapies. Therefore we welcome all possibilities. Although it is FDA approved, hopefully we will hear about EMA approval soon! Read the whole Press Release here.